V. Grumberg
41 works · 203 citations · h-index 6
Top works
- 1276P Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): Real-world 3-year outcomes within overall and special populations (the UNIVOC study)
- Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis
- A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health Authorities
- Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study)
- Exploring the Health-Related Quality of Life of Patients Treated With Immune Checkpoint Inhibitors: Social Media Study
- Machine Learning–Based Analysis of Treatment Sequences Typology in Advanced Non–Small-Cell Lung Cancer Long-Term Survivors Treated With Nivolumab
- MA07.06 Immunotherapy Re-Challenge After Nivolumab Treatment in Advanced Non-Small Cell Lung Cancer in French Real-World Setting
- Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting
- Long-term hospital resource utilization and associated costs of care for patients initiating nivolumab in advanced non-small cell lung cancer in France
- P2.04-03 Nivolumab Outcomes in Octogenarian Patients with Advanced Non-Small Cell Lung Cancer in French Real-World Setting
- 101P Nivolumab outcomes in interstitial lung disease patients with advanced non-small cell lung cancer in French real-world setting
- Clinical benefit of anti-PD-(L)1 immunotherapies in advanced cancer in France: a population-based estimate from 2014 to 2021
- Characteristics, management, and healthcare resources of patients with advanced non–small-cell lung cancer surviving 5 years after nivolumab treatment initiation: A national database analysis
- PCN464 HEALTH-RELATED QUALITY OF LIFE (HRQOL) OF CANCER PATIENTS TREATED WITH IMMUNOTHERAPY: USE OF SOCIAL MEDIA IN FRENCH LANGUAGE TO EXPLORE RELEVANCE OF CONCEPTS COVERED BY CANCER GENERIC HRQOL MEASURES
- Organizational Impact of Immunotherapies in Advanced Cancers in France
- EPH186 Public Health Impact of Immunotherapies in Advanced Cancers in France: A National Retrospective Estimate Until End of 2020
- Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): A French nationwide retrospective cohort (UNIVOC Study)
- Patients en vie 5 ans après l’initiation de nivolumab dans le cancer bronchique non à petites cellules métastatique : caractéristiques, prise en charge et consommations de soins
- Re-challenge de l’immunothérapie en vie réelle après un traitement par nivolumab dans le traitement du cancer bronchique non à petites cellules (CBNPC) à un stade avancé en France (étude UNIVOC)
- Prise en charge des patients avec un cancer bronchique avancé et vivants deux ans après un traitement par nivolumab en deuxième ligne ou plus : intérêt des techniques de « Machine learning »